Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 05:40PM GMT
Release Date Price: €27.85 (-15.45%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Good morning, everybody. Thank you so much for joining us on the last day of the Bank of America Annual Healthcare Conference in Las Vegas. My name is Jason Gerberry. I'm one of the biotech analysts at BofA, and I am pleased to be introducing our next company presenter for a fireside chat, Arrowhead Pharmaceuticals and CEO, Chris Anzalone.

So Chris, first off, thank you for joining us.

Christopher R. Anzalone
Arrowhead Pharmaceuticals, Inc. - CEO, President & Director

Thanks very much. It's great to be here.

Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Yes. Great. So maybe first off, just coming off of the quarter update, few pipeline updates, few updates just regarding maybe manufacturing. I don't know if you have any prepared remarks or just want to maybe kind of run through the latest highlights on Arrowhead before we jump into maybe more specific questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot